Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
7
×
san francisco blog main
san francisco top stories
7
×
biotech
national
new york blog main
new york top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
crispr therapeutics
merck
pfizer
president trump
roche
abbvie
albert bourla
bristol-myers squibb
cancer immunotherapy
crispr
What
today
7
×
cancer
crispr
drug
annual
big
bio
biotech
cas
clinical
future
new
oncology
potential
roundup
society
acquisitions
ahead
aiming
albert
ambien
ambys
american
asco
attendees
attention
available
away
based
biggest
biosciences
bourla
breast
bringing
camp’s
cancer's
cash
cells
ceo
ceos
Language
unknown
unset
Current search:
today
×
photo
×
" national top stories "
×
" san francisco top stories "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More